Wickham Laboratories expands sterility testing facilities
29 November 2016 | By Wickham Laboratories Limited
Wickham Laboratories completes facility expansion for growing sterility department...
List view / Grid view
News
FDA approval for Sanofi’s Soliqua to treat type 2 Diabetes
29 November 2016 | By Niamh Louise Marriott, Digital Editor
Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, studied in a Phase 3 program...
EC approves Teva’s Acute Promyelocytic Leukaemia drug
28 November 2016 | By Niamh Louise Marriott, Digital Editor
It is the first time that a form of acute leukaemia can be effectively treated with a regimen that is entirely chemotherapy-free...
Edinburgh Instruments receive Scottish Business Pledge Accreditation
24 November 2016 | By Edinburgh Instruments
Edinburgh Instruments are pleased to announce that we have been accepted to the Scottish Business Pledge, as part of its ongoing commitment to delivering fairness and equality in the work place...
Dolomite’s Fluidic Factory recognized with R&D 100 Award
24 November 2016 | By Dolomite
Dolomite is celebrating the success of its Fluidic Factory 3D printer in the ‘Processing and Prototyping’ category this year’s R&D 100 Awards...
AstraZeneca head and neck cancer trials resume as FDA lifts clinical hold
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The Phase III KESTREL trial has already re-opened for new patient enrolment at some clinical study sites and the EAGLE trial is expected to resume shortly....
Linkam launch the Optical DSC450 for the simultaneous visualisation of thermal transition experiments for improved materials characterisation
23 November 2016 | By Linkam Scientific Instruments Limited
Linkam Scientific Instruments, announce the launch of their Optical DSC450 which enables simultaneous visualization of thermal processes...
ViiV Healthcare to evaluate injectable HIV treatment
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The two studies, FLAIR and ATLAS, will examine the safety and efficacy of monthly dosing with the two-drug, injectable regimen in both treatment-naïve...
Hikma and Vectura to develop and license generic salmeterol for US market
22 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Generic salmeterol is a generic long acting beta‐agonists for the treatment of asthma and COPD, delivered using Vectura’s proprietary dry powder inhalation...
Bellicum recommended for $16.9 million Texan cancer research award
22 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The Institute of Texas award would fund a 3 year global clinical program of clinical trials for adult and paediatric patients acute myeloid leukaemia...
FPS still looks ahead
21 November 2016 | By F.P.S. Food and Pharma Systems Srl
FPS is pleased to announce the enlargement of his production plant...
NICE recommends faecal immunochemical tests for colorectal cancer
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
FITs are considered to be accurate because unlike other tests, they use immunochemical detection methods that are specific to human haemoglobin...
Boehringer Ingelheim’s bevacizumab biosimilar demonstrates bioequivalence
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
BI 695502, a bevacizumab biosimilar candidate to Avastin, is a monoclonal antibody that may slow or stop the growth of certain tumour types by preventing...
Sanofi and Regeneron’s rheumatoid arthritis drug shows superior results
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Sanofi and Regeneron presented results of a Phase 3 study demonstrating the superiority of investigational sarilumab monotherapy versus adalimumab...
Price discount helps give green light for Roche’s breast cancer drug
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A discount to the price of pertuzumab agreed with the company was an important factor in enabling NICE to overturn its earlier provisional decision...
